Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615 1617 1621 1627 1628 1629
This examiner grants 60% of resolved cases
San Ming R. Hui is an experienced examiner in Art Unit 1615, Tech Center 1600, with 1317 resolved cases. He has an allowance rate of 59.5%, suggesting a balanced prosecution environment for applicants. The median days to allowance is 1085, which is a standard duration for the patent office. With 1317 resolved cases, these metrics are highly reliable and reflect a consistent examination style in this art unit.
The interview lift of 20.1% is a significant factor, indicating that interviews are a very effective tool for success. This lift can help improve the 59.5% base allowance rate considerably through direct engagement. Practitioners should use the 1085-day timeline to manage client expectations in Tech Center 1600. The 20.1% lift suggests that oral advocacy is a productive method for resolving technical disagreements. Given the large volume of 1317 cases, the 59.5% allowance rate is a stable baseline. Strategy should involve a proactive approach to interviews to maximize the probability of a grant within the 1085-day window.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18739657 | COMBINATION | Non-Final OA | Novartis AG |
| 18589673 | COMPOSITIONS AND METHODS FOR TREATING PAIN IN ANIMALS | Final Rejection | North Carolina State University |
| 18574883 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | Non-Final OA | KYOTO UNIVERSITY |
| 18640382 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | Non-Final OA | Incyte Corporation |
| 18632667 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | Non-Final OA | NeuroDerm, Ltd. |
| 17478112 | COMPOSITIONS AND METHODS FOR TREATING NONINFECTIOUS UVEITIS | Non-Final OA | CLEARSIDE BIOMEDICAL, INC. |
| 18289513 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Non-Final OA | NURIX THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy